Intuitive Surgical, Inc. $ISRG Stock: Formuepleje A S Boosts Position

Formuepleje A S lifted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 41.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,757 shares of the medical equipment provider’s stock after acquiring an additional 1,403 shares during the period. Formuepleje A S’s holdings in Intuitive Surgical were worth $1,934,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Invesco Ltd. boosted its position in shares of Intuitive Surgical by 17.4% during the fourth quarter. Invesco Ltd. now owns 4,128,735 shares of the medical equipment provider’s stock valued at $2,338,350,000 after purchasing an additional 611,268 shares in the last quarter. Bank of America Corp DE grew its stake in Intuitive Surgical by 3.3% in the first quarter. Bank of America Corp DE now owns 3,616,973 shares of the medical equipment provider’s stock worth $1,667,388,000 after purchasing an additional 116,292 shares during the period. Bank of New York Mellon Corp purchased a new stake in Intuitive Surgical in the second quarter worth $1,335,753,000. J. Stern & Co. LLP raised its holdings in Intuitive Surgical by 18,504.6% in the fourth quarter. J. Stern & Co. LLP now owns 2,127,248 shares of the medical equipment provider’s stock worth $1,204,788,000 after purchasing an additional 2,115,814 shares in the last quarter. Finally, Amundi raised its holdings in Intuitive Surgical by 8.6% in the first quarter. Amundi now owns 2,428,356 shares of the medical equipment provider’s stock worth $1,119,448,000 after purchasing an additional 193,096 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Gary Loeb sold 400 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $379.00, for a total value of $151,600.00. Following the sale, the executive vice president directly owned 5,320 shares of the company’s stock, valued at approximately $2,016,280. The trade was a 6.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy Ladd sold 400 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $379.00, for a total value of $151,600.00. Following the completion of the sale, the director directly owned 251 shares in the company, valued at approximately $95,129. This represents a 61.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 12,370 shares of company stock valued at $4,891,989 in the last ninety days. Corporate insiders own 0.60% of the company’s stock.

Wall Street Analyst Weigh In

ISRG has been the subject of several recent research reports. HSBC lowered Intuitive Surgical from a “buy” rating to a “hold” rating and set a $391.00 price objective for the company. in a research report on Thursday, July 30th. UBS Group reaffirmed a “buy” rating on shares of Intuitive Surgical in a research report on Tuesday. KeyCorp reaffirmed an “overweight” rating on shares of Intuitive Surgical in a research report on Wednesday, August 12th. Evercore set a $430.00 price target on shares of Intuitive Surgical in a research note on Monday, July 6th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Intuitive Surgical from $550.00 to $450.00 and set an “overweight” rating for the company in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and an average target price of $498.83.

Intuitive Surgical Stock Performance

Shares of ISRG traded up $5.12 during mid-day trading on Thursday, reaching $425.36. The company had a trading volume of 831,960 shares, compared to its average volume of 2,402,024. The firm has a 50-day moving average price of $389.39 and a 200 day moving average price of $409.80. Intuitive Surgical, Inc. has a 52 week low of $328.57 and a 52 week high of $603.88. The company has a market capitalization of $150.27 billion, a price-to-earnings ratio of 48.77, a price-to-earnings-growth ratio of 3.18 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.48 by $0.32. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%. The company had revenue of $2.89 billion for the quarter, compared to the consensus estimate of $2.83 billion. During the same quarter in the prior year, the business posted $1.81 EPS. The firm’s quarterly revenue was up 18.4% compared to the same quarter last year. As a group, research analysts forecast that Intuitive Surgical, Inc. will post 8.87 earnings per share for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops and commercializes robotic-assisted systems and related technologies designed to support minimally invasive medical procedures. The company’s products are intended to help surgeons perform operations through small incisions while providing enhanced visualization, precision, and control.

Its principal product is the da Vinci Surgical System, a platform used across a range of specialties, including general surgery, urology, gynecology, thoracic surgery, and cardiac procedures.